News & Blog

So You Heard About Rintega? Here’s What’s Next for Brain Tumor Drug Development

Last week, news broke that a promising clinical trial of a new type of treatment for a subset of glioblastoma (GBM) patients – an immunotherapeutic vaccine made by Celldex Therapeutics called RINTEGA (rindopepimut) – was discontinued because patients receiving the investigational therapy were not doing better than patients in the control arm. As we said in our statement regarding […]

From the CEO’s Desk: Busy Season for Public Policy Kicks Into Gear

The first quarter of the year for the National Brain Tumor Society (NBTS) – and any other organization engaged in proactive advocacy – is a particularly busy time in the area of public policy and government relations. While research initiatives often spillover year-to-year and remain ongoing (like our flagship research initiative, the Defeat GBM Research Collaborative, which is a […]

A Roadmap for a Successful 2016: Focus. Community. Leadership.

Just like the President of the United States, governors and mayors across country who take every January to deliver State of the Union/State/City addresses, I didn’t want to let this month slip by without letting all of you – our valued community – know how NBTS plans to make the most of the trust, time, […]

Share